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Background Treatment of patients with ULMCA
(unprotected left main coronary artery disease) with
percutaneous coronary intervention (PCI) has been
compared with coronary artery bypass graft (CABG),
without conclusive results.
Methods All randomized controlled trials (RCTs) and
observational studies with multivariate analysis comparing
PCI andCABG forULMCAwere included.Major cardiovascular
events (MACEs, composite of all-cause death, MI, definite or
probable ST, target vessel revascularization and stroke) were
the primary end points, whereas its single components were
the secondary ones, along with stent thrombosis, graft
occlusion and in-hospital death and stroke. Subgroup
analyses were performed according to Syntax score.
Results Six RCTs (4717 patients) and 20 observational
studies with multivariate adjustment (14597 patients) were
included. After 5 (3–5.5) years, MACE rate was higher for
PCI [odds ratio (OR) 1.10, 95% confidence interval (CI)
1.07–1.14], without difference in death, whereas more
relevant risk of MI was because of observational studies.
Coronary stenting increased risk of revascularization (OR
1.52; 95% CI 1.34–1.72). At meta-regression, performance
of PCI was improved by use of intra-coronary imaging and
worsened by first generation stents, whereas two arterial
grafts increased benefit of CABG. For patients with Syntax
score less than 22, MACE rates did not differ, whereas for
higher values, CABG reduced MACE because of lower risk
of revascularization. Incidence of graft occlusion was 3.24%
(2.25–4.23), whereas 2.13% (1.28–2.98: all CI 95%) of
patients experienced stent thrombosis.
Conclusion Surgical revascularization reduces risk of
revascularization for ULMCA patients, especially for those
with Syntax score greater than 22, with a higher risk of in-
hospital death. Intra-coronary imaging and use of arterial
grafts improved performance of revascularization
strategies.
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Introduction
The high risk related to stenosis of unprotected left main
coronary artery (ULMCA) and its negative prognostic
impact is largely known. This condition is reported in
about 6% of patients undergoing coronary angiography
both for acute coronary syndromes as in stable angina.1
Coronary artery bypass grafting (CABG) has long been
considered the treatment of choice for ULMCA.2 Devel-
opment of drug-eluting stents (DESs) and use of imaging
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techniques increased use of percutaneous coronary inter-
vention (PCI) with satisfactory results even at long-term
follow-up.3,4 Some randomized controlled trials (RCTs)
compared PCI and CABG demonstrating similar results
in terms of death, myocardial infarction (MI) and stroke
with a benefit of CABG in terms of lower subsequent
revascularization.5,6 Use of multiple arterial grafts and of
new generation DESs has been advocated by cardiac
surgeons and interventional cardiologists, respectively,
as a promising strategy in this field, but contrasting data
have been recently provided.7,8 A recent meta-analysis
based only on RCTs and including last published articles
with newest DESs generation confirmed similar efficacy
between the two approaches except for higher repeated
revascularization with PCI.9 Data from observational
studies with multivariate adjustment may be of interest,
in order to increase the body of evidence expanding the
sample size from one side, and to test the reproducibility
of RCTs results to real life patients, often excluded from
RCTs.10
The aim of this meta-analysis is to overcome the lack of
clear scientific evidence by pooling data from available
RCTs, propensity-score-adjusted trials and studies per-
forming Cox multivariate analysis.
Methods
The present study was performed according to Preferred
Reporting Items for Systematic Reviews and Meta-Anal-
yses statements (PRISMA).11–15 PubMed, Cochrane, and
Google Scholar were searched for the following terms:
‘coronary artery bypass’ and ‘coronary stenting’ and ‘mul-
tivessels disease’ and ‘left main disease’ by two authors
(M.B. and O.D.F.). Citations were first screened inde-
pendently by two reviewers (M.I. and F.D.A.), with
disagreements resolved by consensus. Inclusion criteria
were human studies, comparing PCI with CABG for left
main revascularization, with a follow-up longer than
3 years and more than 50 included patients to avoid
limited sample effect. In the case of duplicate reporting,
the manuscript with the largest sample of patients was
selected. By authors’ choice, articles not written in
English were excluded from this analysis.
Data abstraction
The following data were independently abstracted by
two reviewers (M.I. and F.D.A.) on prespecified elec-
tronic forms, with disagreements resolved by consensus:
authors, journal, year of publication, location of the study
group, type of DES, baseline, angiographic and proce-
dural features, kind of bypass graft and definition of
bleeding were collected. The corresponding authors of
the relevant studies were queried to provide quantitative
details not available in the published manuscripts and
were included in the project (see appendix, web only,
http://links.lww.com/JCM/A134).
End points
Major cardiovascular events [MACEs: composite of all-
cause death, MI, definite or probable ST, target vessel
revascularization (TVR)] was the primary end point,
whereas its single components were the secondary ones,
along with graft occlusion, target lesion revascularization
(TLR) and in-hospital death and stroke. Subgroup anal-
yses for MACEs, death and revascularization were per-
formed according to Syntax score. Meta-regression
analysis was performed to evaluate impact of site of
stenosis and of choice of strategies on revascularization.
Quality study evaluation
The quality of included studies was independently
appraised by two reviewers (M.I. and F.D.A.), with dis-
agreements resolved by consensus. For each RCT, we
evaluated the risk of bias (low, moderate, unclear, or high)
for random-sequence generation, allocation concealment,
blinding of patients and physicians, blinding during
assessment of follow-up, incomplete outcome evaluation,
and selective reporting, in keeping with the Cochrane
Collaboration approach (see appendix, table S1-S2, web
only, http://links.lww.com/JCM/A134).
Statistical analysis
Continuous variables are reported as mean (SD) or
median (first and third quartile). Categorical variables
are expressed as n (%). Statistical pooling for incidence
estimates was performed according to a random-effect
model with generic inverse-variance weighting, comput-
ing risk estimates with 95% confidence intervals (CIs),
using RevMan 5.2 (The Cochrane Collaboration, The
Nordic Cochrane Centre, Copenhagen, Denmark). Small
study bias was appraised by graphical inspection of funnel
plots. Meta-regression analysis was performed to assess
the impact of baseline features on the primary end point
with comprehensive meta-analysis software (trial ver-
sion). Hypothesis testing for superiority was set at the
two-tailed 0.05 level. Hypothesis testing for statistical
homogeneity was set at the two-tailed 0.10 level and
based on the Cochran Q test, with I2 values of 25, 50, and
75% representing mild, moderate, and severe heteroge-
neity, respectively.
Statistical methods and baseline and interventional vari-
ables included in the propensity score matching/multi-
variate analysis of observational studies are described in
appendix table S6 A-B (web only), http://links.lww.com/
JCM/A134.
Results
Studies selection and baseline features
A total of 2358 results emerged from the key research
used. After an accurate analysis of title, abstract and, if
necessary, full-text, 2332 works were excluded as they
did not full-fill inclusion criteria previously stated. In
particular, 2077 were ruled out as not pertinent, 34 were
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not in English, 95 results were editorials/case report/
reviews, 50 were neither RCTs nor multivariate adjusted
studies, 58 had an inadequate follow-up (<3 years) and 2
studies were excluded because of a small sample size (<50
patients). Of 42 results first selected, 16 were then judged
as redundant as conducted among a population enrolled in
a larger trial. Twenty-six articles were finally selected for
the systematic review and meta-analysis: 6 RCTs and 20
observational studies with multivariate adjustment or pro-
pensity score analysis (NRCTs) (see appendix, web only,
http://links.lww.com/JCM/A134). Nineteen thousand
three hundred and fourteen patients were included in
the final analysis, of which 8501 were treated with PCI
and 10813 with CABG. Four thousand seven hundred and
seventeen patients were enrolled in RCTs (2360 in PCI
group and 2357 in CABG group) and 14597 in NRCTs
(6141 in PCI group and 8456 in CABG group, see Fig. 1).
Mean age of overall population was 64 9 years; 26%
were women, 64% were hypertensive patients, and 32%
were diabetic. Median Syntax score was 26, whereas
single-study Euroscore value and type are described in
Table S4A (web appendix only, http://links.lww.com/
JCM/A134); 12% of the patients had a single lesion of
left main, whereas distal left main stenosis was reported
in 65% of them (see Tables 1 and 2 for overall data and
Table S4-S5, web appendix only, for specific single-study
data, http://links.lww.com/JCM/A134).
Primary endpoint analysis
Twenty-two of the 26 included studies (6 RCTs includ-
ing 4717 patients and 16 NRCTs for 13 375 patients)
556 Journal of Cardiovascular Medicine 2018, Vol 19 No 10
Fig. 1
Id
en
ti
fi
ca
ti
o
n
S
cr
ee
n
in
g
E
le
g
ib
ili
ty
In
cl
u
d
ed
2358 results identified through database 
(Pubmed/Google scholar/Cochrane) 
searching and screened
42 papers evaluated for 
eligibility
2332 works excluded, not meeting inclusion criteria 
– 2077 not pertinent
– 95 editorial/case reports/reviews
– 50 not RCTs/multivariate propensity
– 58 inadequate follow up ( < 3 years)
– 2  small sample size (< 50 patients)
– 34 not in English
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16 full text articles excluded since redundant 
(population enrolled in larger trials)
Study design and review’s profile. Twenty-six articles were finally selected for the systematic review and meta-analysis, 6 randomized controlled trials
(RCTs) and 20 observational studies with multivariate adjustment or propensity score analysis (NRCTs) with a total of 19 314 patients included in the
analysis, of which 8501 treated with PCI and 10 813 with CABG. PCI, percutaneous coronary intervention.
Table 1 Baseline features of included patients
Total population, n¼19 314
(PCI 8501, CABG 10813)
Age (years) 649
Female (%) 26 (21–29)
Diabetes (%) 32 (26–39)
Hypertension (%) 64 (58–68)
Hyperlipidemia (%) 54 (51–70)
BMI 262
Family history of CAD (%) 178 (9–19)
Current smokers (%) 35 (20–48)
Previous AMI (%) 22 (7–41)
EF 556
Previous PCI (%) 16 (9–29)
Previous stroke (%) 9 (2–13)
BPCO (%) 5 (1–7)
Periferal vascular disease (%) 10 (2–17)
IRC (%) 8
Syntax score 265
Clinical presentation
STEMI 2.24%
NSTEMI 1216%
UA 4618%
Stable angina 3717%
Silent ischemia 2.82
AMI, acute myocardial infarction; BMI, body mass index; BPCO, chronic obstruc-
tive pulmonary disease; CABG, coronary artery bypass graft; CAD, coronary artery
disease; EF, ejection fraction; IRC, chronic renal insufficiency; NSTEMI, non ST
elevation myocardial infarction; PCI, percutaneosu coronary intervention; STEMI,
ST elevation myocardial infarction; UA, unstable angina.
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evaluated the incidence of MACEs in the two groups
(8055 patients for PCI group and 10 037 for CABG group).
After 5 (3–5.5) years, the overall incidence of events was
higher in the PCI group compared with the CABG group
(OR 1.10, 95% CI 1.07–1.14, P< 0.01). This result was
confirmed in both NRCTs (OR 1.11; 95% CI 1.07–1.16,
P< 0.00001), and RCTs subgroups (OR 1.07; 95% CI
1.01–1.14, P¼ 0.03; see Fig. 2 and S2 in web appendix,
http://links.lww.com/JCM/A134) and considering only
studies not including revascularization in the MACE
definition (see Figure S1 in web appendix, http://
links.lww.com/JCM/A134).
Secondary endpoint analysis
All the studies selected for the primary endpoint were
also included in the analysis of death. According to death
there was a not significant trend for higher incidence in
the CABG group in the general analysis (OR 0.94; 95%CI
0.89–1.00, P¼ 0.05), with a neutral result in the sub-
groups (OR 0.92; 95% CI 0.78–1.07; P¼ 0.27; and OR
0.95; 95% CI 0.89–1.02; P¼ 0.14, respectively for RCTs
and NRCTs; see Fig. 3, panel a)
All RCTs and seven NRCTs (total patients 12 129, 7412
from NRCTs and 4717 from RCTs; 5278 for PCI, 8284
for CABG) evaluated incidence of MI. There was a
significant higher incidence of MI in patients undergoing
PCI compared with those re-vascularized by CABG (OR
PCI versus CABG in ULMCA Bertaina et al. 557
Table 2 Interventional features of included patients
Procedural features
Total population, n¼19 314
(PCI 8501, CABG 10813)
Distal left main 65 (54–74)
Only left main 12 (2–21)
First generation DES/BMS 83 (80–84)
Use of IVUS 63 (40–81)
Final kissing balloon 46 (30–51)
On pump surgery 64 (45–71)
Two arterial grafts 50 (16–64)
Complete revascularization 84 (78–82)
BMS, bare metal stents; CABG, coronary artery bypass graft; DES, drug eluting
stents; IVUS, intravascular ultrasound; PCI, percutaneous coronary intervention.
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1.22; 95% CI 1.11–1.35, P< 0.00001). This result was
substantially determined by NRCTs (OR 1.32; 95% CI
1.17–1.49, P< 0.00001), whereas there was a nonsignifi-
cant trend favourable to CABG in RCTs (OR 1.12; 95%
CI 0.97–1.29, P¼ 0.14; see Fig. 3, panel b) also excluding
the NOBLE study (see Figure S2, web appendix, http://
links.lww.com/JCM/A134).
Seventeen studies (6 RCTs and 11NRCTs, total patients
14 342, 4717 from RCTs and 9625 fromNRCTS, 6509 for
PCI, 7992 for CABG) were included for revascularization.
The overall rate was significantly higher in the PCI group
(OR 1.52; 95% CI 1.34–1.72; P< 0.00001) than in the
CABG group (see Fig. 3c). This result was confirmed in
both subgroups: OR 1.25; 95%CI 1.16–1.36 (P< 0.01) for
RCTs and OR 1.69; 95% CI 1.46–1.95 (P< 0.01) for
NRCTs. Similarly, PCI increased risk of TLR and ische-
mia-driven revascularization (see Fig. 4).
At meta-regression analysis, the use of two arterial graft or
first generation drug eluting stents (DES) correlated with
the higher incidence of repeated revascularization with
PCI [beta 0.15 (0.12–0.18) and 0.2 (0.15–0.24)], respec-
tively, for two arterial grafts and use of first generation
DES. Distal left main resulted not significant [beta 0.08
(0.02–1.7), P¼ 0.51], whereas use of intravascular ultra-
sound (IVUS) was protective [beta 0.02 (0.09 to
0.01); see Fig. 5a–c].
Regarding in-hospital events, from the analysis of 10
studies (of which two were RCTs), PCI reduced risk
of death (OR 0.70; 95% CI 0.57–0.86, P< 0.01), as well as
stroke (OR 0.59; 95% CI 0.38–0.93; P¼ 0.02; see Figure
S4, web appendix, http://links.lww.com/JCM/A134).
Finally, 12 studies (four RCTS) reported the incidence of
stent thrombosis (total patients 6542, 2208 from RCTs
and 4334 from NRCTs) whereas 6 (3 RCTs) described
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rate of graft occlusion (3007 total patients, 1903 from
RCTs, 1104 NRCTs). The analysis of these data showed
a higher incidence of graft occlusion compared with
definite or probable stent thrombosis, respectively,
3.24% (2.25–4.23) for graft occlusion and 2.13% (1.28–
2.98) for stent thrombosis (see Fig. 6a and b). Specific
outcomes definition and data on a single-study basis are
described in supplementary appendix (see Tables S5-S7,
web appendix, http://links.lww.com/JCM/A134).
Subgroup analysis for Syntax score
Five studies evaluated (two RCTs and three NRCTs,
2886 patients in PCI group, 4398 in CABG group)
MACEs in patients with a Syntax score less than 22
showing similar outcomes between the two strategies
(OR 1.15; 95% CI 0.98–1.35, P¼ 0.08).
Two thousand five hundred and thirty-three patients,
1087 in the PCI group and 1446 in the CABG
group, with an intermediate Syntax score (22–32)
were analysed in three studies (two RCTs). MACE
rate was higher in the PCI group (OR 1.26; 95% CI
1.05–1.5; P¼ 0.01). An analogue result was obtained
for patients with a Syntax score > 32, from a meta-
analysis of two RCTs and two NRCTs including this
high-risk population (total patients 6956; PCI 2766,
CABG 4190) (OR 1.27: 1.19–1.36; P< 0.0001). All
these results did not change removing NRCTs from
the analysis.
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Three studies (of which two were RCTs) reported the
incidence of death among patients with a Syntax score
less than 22. There was a nonsignificant higher incidence
of all-cause death in patients treated with PCI (OR 1.43;
95% CI 0.82–2.51, P¼ 0.21). Only one RCT was avail-
able for intermediate Syntax score (22–32), with higher
risk for PCI (OR 1.28; 95% CI 1.21–1.36, P< 0.00001).
Three articles (two RCTs) were included for high-risk
patients (Syntax >32) without difference (OR 1.04; 95%
CI 0.43–2.52, P¼ 0.92). For this subgroup, the exclusion
of NRCTs from the analysis did not significantly change
the result.
A subgroup analysis for Syntax score was also performed
for revascularization. Three trials (two RCTs involving
5351 patients, 2099 for PCI and 3252 for CABG) reported
this endpoint for patients with Syntax score less than 22,
resulting in a nonsignificant higher incidence of revascu-
larization for the PCI group (OR 1.43; 95% CI 0.82–2.51,
P¼ 0.21). Result reached statistical significance after
excluding NRCT (OR 1.11; 95% CI 1.08–1.14). More
repeated revascularizations were also observed in
patients with intermediate Syntax score (OR 1.28; 95%
CI 1.21–1.36, P< 0.00001). One RCT was available as
well with Syntax score greater than 32 (OR 1.71; 95% CI
1.55–1.89, P< 0.0001, from two RCTs and one NRCT,
see figures S5, web appendix, http://links.lww.com/JCM/
A134).
Discussion
To the best of our knowledge, this is the first meta-
analysis including data from all RCTs comparing PCI
versus CABG for ULMCA, along with data from obser-
vational studies with multivariate adjustment.
The main results were:
(1) At a mean follow-up of 5 years, there were more
MACEs with PCI strategy than CABG; this result is
mainly driven by a higher incidence of repeated
revascularization particularly in case of complex
lesions (Syntax score 22);
(2) The difference in terms of repeated revascularization
was more evident using first generation DES and for
patients treated with two arterial conduits, whereas
use of IVUS improved performance of PCI;
(3) Stroke incidence and hospital death were higher with
CABG strategy.
At a medium- to long-term follow-up, patients who
underwent ULMCA revascularization with PCI showed
a slightly higher (10% increase) incidence of MACE.
Even ifMACE represented a widespread used composite
endpoint in the scientific community, thanks to its ability
to reduce the sample size needed by researchers, its
heterogeneous definition generated important diver-
gences in result interpretation.16 For example, the two
recently publishedRCTs on this theme, theNOBLE and
EXCEL trials,2,6 showed apparent discordance in terms
of primary composite outcome that can probably be
justified by the inclusion of revascularization in the first
and the exclusion in the second one. Focusing on single
component outcome, our meta-analysis highlighted that
although no significant differences emerged in terms of
overall mortality, revascularizations were more frequent
with PCI strategy both in randomized and in nonrandom-
ized studies, whereas reduction of MI offered by CABG
was evident only after adding observational studies.
These results were substantially consistent with all pre-
viously published studies and meta-analysis2,5 even if
only Athappan et al.17 evidenced a trend for more MI
with PCI.
Correlation between lesion complexity and outcome
has been confirmed by the present analysis. In the
Syntax score subanalysis, the statistical significance for
the need for new revascularization at follow-up was
achieved for Syntax score 22 with a subsequent clear
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linear correlation for incremental values. This report
was well known since Syntax score publication18 and
clearly implemented in European and American guide-
lines indication.19,20 Similarly, our data demonstrated
that in patients with low Syntax score, rates of revas-
cularization did not differ among PCI and CABG,
whereas risk of death did not differ across the sub-
groups.
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Specific revascularization techniques influenced the risk
of subsequent revascularization. According to our meta-
regression analysis, the higher incidence of revasculari-
zation in PCI patients was more evident with the use of
first generation DESs and when compared with those
treated with two arterial grafts, whereas it was reduced by
the use of IVUS. The majority of studies considered in
our meta-analysis used first generation DES. Last gener-
ation DESs, with their more biocompatible structure,
have been shown to have the potentiality to decrease
incidence of repeated revascularizations, stent thrombo-
sis and consequently MACEs in head-to-head compari-
son versus previous generation, even if mainly in other
lesion settings8,21,22 with little evidence on left main
treatment23–26 and in terms of PCI versus CABG com-
parison.2,6 The NOBLE and EXCEL trials compared
Biolimus-eluted stent (BES) and fluoro-polymer-based
cobalt–chromium everolimus-eluting stents (EES),
respectively, to CABG strategy. At a mean follow-up of
5 and 3 years, patients in PCI cohorts needed more
repeated revascularization and experience more nonpro-
cedural MI. Of note, a significant difference emerged
only for total revascularization, whereas TLR were simi-
lar between the two groups. These findings confirmed a
good outcome of PCI with new DESs on left main
lesions, whereas the repeated revascularizations were
probably because of CAD progression in other sites. More
data with the use of new DESs are needed to better
clarify these results. Moreover, benefit of use of IVUS is
largely known with DES,4,27 as a means to optimize
procedural performance, resulting in improved long-term
clinical outcomes. On the other hand, the use of multiple
arterial grafting seemed to increase CABG benefit in our
analysis. This result is consistent with a very large amount
of observational evidence.28 However, the recently pub-
lished interim 5-year analysis of the ART trial7 did not
find any survival benefit with the use of bilateral mam-
mary artery graft with a concomitant increase in wound
complications. The lack of power to detect significant
differences in hard outcomes at 5 years’ follow-up, the
high rate of cross-over between groups, the use of the
radial artery in almost 30% of the patients in the single
mammary group and the exceptionally high compliance
with optimal medical therapy can probably explain the
negative results of this article. It is reasonable to suppose
that multiple arterial grafting, whenever technically fea-
sible and especially in younger patients, could give a
long-term benefit compared with venous bypass and
single internal mammary artery and to PCI as suggested
by our meta-analysis.
The higher incidence of stroke in CABG patients
stressed the importance of a tailored approach for the
choice between percutaneous and surgical revasculariza-
tion. The present result confirmed those previously evi-
denced by several meta-analyses17,29 and can probably be
linked to the higher in-hospital mortality with CABG that
emerged in our study. Consequently, whenever evaluat-
ing a patient with ULMD, the risk of in-hospital compli-
cation according to single-patient risk should be carefully
weighed against that of subsequent revascularization, also
according to Syntax score.
Limitation
Our study presents many limitations. As results were
analysed on an aggregate data basis, no assessment of
between-group equal distribution of baseline character-
istics was possible. As with any meta-analysis, all
included studies’ limitations are shared by our work;
the statistical heterogeneity among the studies included
in the primary and secondary outcomes’ analysis resulted
as always severe, whereas for publication bias funnel plot
analysis showed that it was not relevant, as confirmed by
nonsignificant Egger’s test (P¼ 0.57; see appendix,
Figure S1, http://links.lww.com/JCM/A134). Finally,
some results show borderline statistical significance so
that a larger sample size as well as a longer follow-up
could increase statistical reliability for the present results.
Conclusion
CABG reduced risk of repeated revascularization com-
pared with PCI in patients with ULMCA, especially for
those with Syntax score more than 22, with a higher risk
of in-hospital death. Use of double arterial grafts
improved performance of CABG as well as intra-coronary
imaging did for PCI approach.
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